Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.
Sarah Anderson
Sarah Anderson is the oncology strategy lead director for Novotech.
Articles by Sarah Anderson
Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments being made with novel biomarkers.
Latest Updated Articles
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
5